about
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a referencePractical management of bevacizumab-related toxicities in glioblastomaImmunotherapy response assessment in neuro-oncology: a report of the RANO working groupEORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial.O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategiesA multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia.Salvage temozolomide for prior temozolomide responders.Temozolomide as salvage treatment in primary brain lymphomas.Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancerDisease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology.Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.Glioblastoma in adults.Chemotherapy in breast cancer patients with brain metastases: have new chemotherapic agents changed the clinical outcome?Association between response to primary treatments and MGMT status in glioblastoma.Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET).Treatment options for recurrent glioblastoma: pitfalls and future trends.Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma.Medulloblastomas in adults: prognostic factors and lessons from paediatrics.End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era.EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.Second surgery for recurrent glioblastoma: advantages and pitfalls.Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts.The role of systemic and targeted therapies in brain metastases.Shedding light on adult medulloblastoma: current management and opportunities for advances.Resistance to antiangiogenic therapies.New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology.Contribution of microRNA analysis to characterisation of pancreatic lesions: a review.Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.Nitrosoureas in the Management of Malignant Gliomas.Patient outcomes following second surgery for recurrent glioblastoma.Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences.Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications.Bevacizumab in recurrent glioblastoma: open issues.Post progression survival in glioblastoma: where are we?Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts.
P50
Q21261312-E4D0CCA9-09D4-4E64-BF7F-39DBB9E8E852Q27015852-A8DEDB6B-614E-4F28-A8AD-73BCBFB3E03DQ28083009-A429C8BD-6CF4-4E1D-8C3B-E0865A34A39CQ33403967-4929E012-8930-4B87-ACEF-E36EB359B0DEQ33409415-C3EDC5C8-F578-481A-B361-2EF8AD7726D3Q34132786-62847953-B75E-4582-AE4D-7F08C3D8E1B0Q35584182-5C42867E-4010-4853-BD26-F523EE7459D9Q36136815-01B2281B-7768-446F-9B3C-90AC4EE93ED0Q36306363-5C2DF857-D0E2-47E5-86DF-3AB282B4BF3FQ36610071-ED17AB9A-F7BE-421B-8628-5C2C08769A6DQ36610166-78B11778-D5B1-4798-8F88-723EDBAA4BDDQ36611825-97BA2A3B-E7A5-498F-83AA-59452B7C507EQ36673717-B30C1CDB-C2D9-49FC-8CFC-C14E771D2D9AQ36926781-BA55A02B-314B-4204-A986-4FE6E7A82337Q37087075-3B5E150C-5A76-4F29-B0AA-D14DE281C48AQ37131407-146FFE9B-9648-40EB-9DF9-E2A6256B642AQ37190196-FD53489B-9D88-47A8-B80B-129129AA5913Q37316991-0006DD7E-BC70-44A6-8EDE-12FF2307B677Q37419741-B51C2245-0974-463E-BF8E-CBCF784C83C0Q37483971-CC44DFE7-83BA-4C95-B043-6583D490C1C8Q37687375-90BED4B1-4367-4324-A69F-82F708D666BEQ37688213-E1C0F9A4-5071-4EDA-AB0B-5E3AC1975133Q37949503-9EEB2C35-4A34-4923-B4B7-ACE4ED6F1C56Q37952239-89C80E2A-B9B5-4E29-A5C1-87B69FBF8240Q38068204-A0EFC916-791E-457C-B1CB-53F9CC084A37Q38101609-385BFB61-291A-43A3-A3C4-2A46931329F2Q38155202-567CA34E-2541-4966-AF5D-D5B4640AD797Q38168919-A704A56E-684D-491B-8206-4F6C692C1E71Q38214322-AC8D6B5B-F6F5-4F28-A16D-571EC8C9A580Q38232852-62C51616-4453-43C2-A018-9C8D8A4CB89EQ38323968-812AAD8F-C2EF-4C22-AB2D-142996B006E5Q38575189-DE5A96B7-0BFB-48C4-A775-40AD1DAC343CQ38658533-368FF11A-6BC6-42E3-BD8D-7F8CA62B9A86Q38691732-94B3C459-0E64-43A2-B78B-AE42ED544058Q38907846-8F230B4D-A3F8-4A5B-AE30-AC417CD3C587Q38909395-E937145A-6EA6-4368-AD3B-2932D435AEEBQ38919700-DE576947-38A3-4CEE-93F8-BFA69C0CDC92Q38965301-4DBBA652-B8A8-4498-80C2-3063FE36A9BAQ39103916-DD3D3759-4563-42B8-A9B6-DC7E9BB3BFACQ39417407-70A2BBE3-D8E0-4835-A591-CBC907135339
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Enrico Franceschi
@ast
Enrico Franceschi
@en
Enrico Franceschi
@es
Enrico Franceschi
@nl
type
label
Enrico Franceschi
@ast
Enrico Franceschi
@en
Enrico Franceschi
@es
Enrico Franceschi
@nl
prefLabel
Enrico Franceschi
@ast
Enrico Franceschi
@en
Enrico Franceschi
@es
Enrico Franceschi
@nl
P106
P1153
35313360400
P21
P31
P496
0000-0001-9332-4677